StonvexLoading…
StonvexStonvexStonvexCore line items from ACMR's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $231.26M | $901.31M | $656.88M | $387.72M |
Operating Income | $36.18M | $109.43M | $86.39M | $57.47M |
Net Income | $17.31M | $94.08M | $86.03M | $50.14M |
EPS (Diluted) | $0.24 | $1.37 | $1.26 | $0.74 |
Total Assets | $3.07B | $2.87B | $2.77B | $2.04B |
Total Liabilities | $982.43M | $941.68M | $885.43M | $848.03M |
Cash & Equivalents | $872.27M | $757.37M | $1.06B | $442.09M |
Free Cash Flow OCF − CapEx | $-51.74M | $-66.61M | $-86.72M | $-71.08M |
Shares Outstanding | 69.77M | 67.31M | 67.55M | 67.14M |